Kolltan Pharmaceuticals Expands Senior Management Team, Appoints Jane Henderson as Senior Vice President & Chief Business Officer

Tools

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the appointment of Jane Henderson as Senior Vice President and Chief Business Officer, effective immediately. Ms. Henderson will report to Gerald McMahon, Ph.D., Kolltan's President and Chief Executive Officer.

"Jane is an important addition to the Kolltan senior team, bringing extensive deal-making and business development experience in the healthcare sector. She will be a key part of our strategy to actively pursue collaborations and other alliances to further expand and develop our first-in-class product pipeline based on the biology of receptor tyrosine kinases," commented Dr. McMahon. "RTK platforms already have resulted in products with a substantial market presence and profound impact on the treatment of cancer patients. We believe that our next-generation approaches, based on the discoveries made by scientific founder Dr. Joseph Schlessinger, represent unique treatments in oncology and other important disease areas."

Arthur G. Altschul, Jr., Kolltan Co-Founder and Chairman of the Board of Directors, stated, "Jane's experience in healthcare, both within leading investment banking firms and at innovator companies, complements the perspectives and expertise of our management team, as well as our highly engaged Board of Directors. Since Kolltan's founding, we have been extremely careful to maintain the company's unique corporate culture, which we believe is essential to the successful development of novel drug therapies based on breakthrough science. Jane's presence and her myriad skills will further enhance our vision, and we are excited to welcome her to the Kolltan team."

Ms. Henderson has more than 24 years of experience in life sciences finance. She most recently served as Vice President, Business Development at ISTA Pharmaceuticals, Inc., where she managed the strategic option process that culminated in the successful acquisition of ISTA by Bausch + Lomb. She also oversaw the identification and evaluation of acquisitions and licensing opportunities and intellectual property strategy at ISTA. Previously, she was Executive Vice President, Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals and served in similar roles at Axerion Therapeutics. Prior to these corporate positions, Ms. Henderson held senior investment banking positions for close to two decades in the health care groups of HSBC Securities, CIBC World Markets, Lehman Brothers and Salomon Brothers. Ms. Henderson represented clients on over 95 M&A and financing deals and attained the level of Managing Director of the Health Care Groups at HSBC and CIBC. Ms. Henderson serves as Secretary/Treasurer and Chairman of the Finance Committee on the Board of The EQUUS Foundation in Westport, CT. She received her B.S. degree in Psychology from Duke University.

About Kolltan Pharmaceuticals

Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is advancing a new generation of therapeutics in oncology and other diseases, based on seminal discoveries made in the laboratory of Dr. Joseph Schlessinger. Kolltan's primary focus is to create novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has approximately 30 employees, and since its inception in 2008, the Company has raised $75 million in equity funding.

 

For more information about Kolltan Pharmaceuticals, please visit www.kolltan.com.
Contacts

Burns McClellan, on behalf of Kolltan Pharmaceuticals
Justin Jackson, 212-213-0006
jjackson@burnsmc.com